When Benign Becomes Cancer: Malignant Degeneration of Chronic Inflammation

Christopher Conlon; Lauren Pupa; Edward M. Reece; Carrie K. Chu; Jessie Z. Yu; Joshua Vorstenbosch; Sebastian Winocour

doi:10.1055/s-0041-1731462

Seminars in Plastic Surgery, Table of Contents

Semin Plast Surg 2021; 35(03): 159-163
DOI: 10.1055/s-0041-1731462

Review Article

When Benign Becomes Cancer: Malignant Degeneration of Chronic Inflammation

Christopher Conlon

¹Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

,

Lauren Pupa

²School of Medicine, Baylor College of Medicine, Houston, Texas

,

Edward M. Reece

¹Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

³Division of Plastic Surgery, Texas Children's Hospital, Houston, Texas

,

Carrie K. Chu

⁴Department of Plastic Surgery, MD Anderson Cancer Center, University of Texas, Houston, Texas

,

Jessie Z. Yu

¹Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

,

Joshua Vorstenbosch

⁵Division of Plastic Surgery, McGill University, Montreal, Canada

,

Sebastian Winocour

¹Division of Plastic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

› Author Affiliations

Abstract

Chronic inflammation, long implicated in the genesis of malignancy, is now understood to underlie an estimated 25% of all cancers. The most pertinent malignancies, to the plastic surgeon, associated with the degeneration of chronic inflammation include Marjolin's ulcer, breast implant-associated large cell lymphoma, radiation-induced sarcoma, and Kaposi's sarcoma. The cellular and genetic damage incurred by a prolonged inflammatory reaction is controlled by an increasingly understood cytokinetic system. Advances in understanding the chronic inflammatory cascade have yielded new therapeutics and therapeutic targets.

Keywords

chronic inflammation - malignant degeneration - Marjolin's ulcer - BI-ALCL - radiation-induced sarcoma - Kaposi's sarcoma

Full Text

References

References
1 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357 (9255): 539-545
2 Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017; 186 (01) 57-62
3 Ikwegbue PC, Masamba P, Mbatha LS, Oyinloye BE, Kappo AP. Interplay between heat shock proteins, inflammation and cancer: a potential cancer therapeutic target. Am J Cancer Res 2019; 9 (02) 242-249
4 Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017; 14 (07) 399-416
5 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14 (10) 1014-1022
6 Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 2010; 5 (01) 30-55
7 Bazaliński D, Przybek-Mita J, Barańska B, Więch P. Marjolin's ulcer in chronic wounds - review of available literature. Contemp Oncol (Pozn) 2017; 21 (03) 197-202
8 Pekarek B, Buck S, Osher L. A comprehensive review on Marjolin's ulcers: diagnosis and treatment. J Am Col Certif Wound Spec 2011; 3 (03) 60-64
9 Kerr-Valentic MA, Samimi K, Rohlen BH, Agarwal JP, Rockwell WB. Marjolin's ulcer: modern analysis of an ancient problem. Plast Reconstr Surg 2009; 123 (01) 184-191
10 Fleming MD, Hunt JL, Purdue GF, Sandstad J. Marjolin's ulcer: a review and reevaluation of a difficult problem. J Burn Care Rehabil 1990; 11 (05) 460-469
11 Copcu E. Marjolin's ulcer: a preventable complication of burns?. Plast Reconstr Surg 2009; 124 (01) 156e-164e
12 Saaiq M, Ashraf B. Marjolin's ulcers in the post-burned lesions and scars. World J Clin Cases 2014; 2 (10) 507-514
13 Asuquo M, Ugare G, Ebughe G, Jibril P. Marjolin's ulcer: the importance of surgical management of chronic cutaneous ulcers. Int J Dermatol 2007; 46 (Suppl. 02) 29-32
14 Gan BS, Colcleugh RG, Scilley CG, Craig ID. Melanoma arising in a chronic (Marjolin's) ulcer. J Am Acad Dermatol 1995; 32 (06) 1058-1059
15 Smith J, Mello LFB, Nogueira Neto NC. et al. Malignancy in chronic ulcers and scars of the leg (Marjolin's ulcer): a study of 21 patients. Skeletal Radiol 2001; 30 (06) 331-337
16 Copcu E, Aktas A, Sişman N, Oztan Y. Thirty-one cases of Marjolin's ulcer. Clin Exp Dermatol 2003; 28 (02) 138-141
17 Kowal-Vern A, Criswell BK. Burn scar neoplasms: a literature review and statistical analysis. Burns 2005; 31 (04) 403-413
18 Beachkofsky TM, Wisco OJ, Owens NM, Hodson DS. Verrucous nodules on the ankle. J Fam Pract 2009; 58 (08) 427-430
19 Møller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol 1979; 115 (06) 703-705
20 Choi JY, Bae YC, Nam SB, Bae SH. Impact of disturbed wound healing after surgery on the prognosis of Marjolin's ulcer. Arch Plast Surg 2013; 40 (03) 198-202
21 Chalya PL, Mabula JB, Rambau P. et al. Marjolin's ulcers at a university teaching hospital in Northwestern Tanzania: a retrospective review of 56 cases. World J Surg Oncol 2012; 10: 38
22 Oruç M, Kankaya Y, Sungur N. et al. Clinicopathological evaluation of Marjolin ulcers over two decades. Kaohsiung J Med Sci 2017; 33 (07) 327-333
23 Kirsner RS, Spencer J, Falanga V, Garland LE, Kerdel FA. Squamous cell carcinoma arising in osteomyelitis and chronic wounds. Treatment with Mohs micrographic surgery vs amputation. Dermatol Surg 1996; 22 (12) 1015-1018
24 Aydoğdu E, Yildirim S, Aköz T. Is surgery an effective and adequate treatment in advanced Marjolin's ulcer?. Burns 2005; 31 (04) 421-431
25 Keech Jr JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg 1997; 100 (02) 554-555
26 Swerdlow SH, Campo E, Pileri SA. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127 (20) 2375-2390
27 Food and Drug Administration. Medical Device Reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Rockville, MD: August 20, 2020. Medical Device Reports
28 Miranda RN, Aladily TN, Prince HM. et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol 2014; 32 (02) 114-120
29 Doren EL, Miranda RN, Selber JC. et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg 2017; 139 (05) 1042-1050
30 de Boer M, van Leeuwen FE, Hauptmann M. et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol 2018; 4 (03) 335-341
31 Ferrufino-Schmidt MC, Medeiros LJ, Liu H. et al. Clinicopathologic features and prognostic impact of lymph node involvement in patients with breast implant-associated anaplastic large cell lymphoma. Am J Surg Pathol 2018; 42 (03) 293-305
32 Magnusson M, Beath K, Cooter R. et al. The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. Plast Reconstr Surg 2019; 143 (05) 1285-1292
33 Clemens MW, Medeiros LJ, Butler CE. et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol 2016; 34 (02) 160-168
34 Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg 2018; 141 (04) 586e-599e
35 McCarthy CMM, Loyo-Berríos N, Qureshi AA. et al. Patient registry and outcomes for breast implants and anaplastic large cell lymphoma etiology and epidemiology (PROFILE): initial report of findings, 2012-2018. Plast Reconstr Surg 2019; 143 (3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): 65S-73S
36 Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J 2019; 39 (Suppl. 01) S3-S13
37 Miller KD, Siegel RL, Lin CC. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66 (04) 271-289
38 Beck A. Zur frage des Rontgensarkoms, Zugleich ein Beitrag zur pathogenese des sarkoms. Munch Med Wochenschr 1922; 69: 623-624
39 Burtt JJ, Thompson PA, Lafrenie RM. Non-targeted effects and radiation-induced carcinogenesis: a review. J Radiol Prot 2016; 36 (01) R23-R35
40 Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005; 104 (04) 856-863
41 Thiagarajan A, Iyer NG. Radiation-induced sarcomas of the head and neck. World J Clin Oncol 2014; 5 (05) 973-981
42 Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist 2012; 17 (03) 405-418
43 Olcina M, Merck B, Giménez-Climent MJ. et al. Radiation-induced leiomyosarcoma after breast cancer treatment and TRAM flap reconstruction. Sarcoma 2008; 2008: 456950
44 Chahin F, Paramesh A, Dwivedi A. et al. Angiosarcoma of the breast following breast preservation therapy and local radiation therapy for breast cancer. Breast J 2001; 7 (02) 120-123
45 Rubino C, Shamsaldin A, Lê MG. et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 2005; 89 (03) 277-288
46 Karlsson P, Holmberg E, Samuelsson A, Johansson KA, Wallgren A. Soft tissue sarcoma after treatment for breast cancer--a Swedish population-based study. Eur J Cancer 1998; 34 (13) 2068-2075
47 Samartzis D, Nishi N, Cologne J. et al. Ionizing radiation exposure and the development of soft-tissue sarcomas in atomic-bomb survivors. J Bone Joint Surg Am 2013; 95 (03) 222-229
48 De Smet S, Vandermeeren L, Christiaens M-R. et al. Radiation-induced sarcoma: analysis of 46 cases. Acta Chir Belg 2008; 108 (05) 574-579
49 Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998; 82 (01) 8-34
50 Callesen LB, Safwat A, Rose HK, Sørensen FB, Baad-Hansen T, Aggerholm-Pedersen N. Radiation-induced sarcoma: a retrospective population-based study over 34 years in a single institution. Clin Oncol (R Coll Radiol) 2021; 33 (05) e232-e238
51 Thijssens KMJ, van Ginkel RJ, Suurmeijer AJH. et al. Radiation-induced sarcoma: a challenge for the surgeon. Ann Surg Oncol 2005; 12 (03) 237-245
52 Erel E, Vlachou E, Athanasiadou M, Hassan S, Chandrasekar CR, Peart F. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast 2010; 19 (05) 424-427
53 Yap J, Chuba PJ, Thomas R. et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002; 52 (05) 1231-1237
54 Neuhaus SJ, Pinnock N, Giblin V. et al. Treatment and outcome of radiation-induced soft-tissue sarcomas at a specialist institution. Eur J Surg Oncol 2009; 35 (06) 654-659
55 Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg 2002; 184 (04) 356-358
56 Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Dermatol Syph 1872; 4 (02) 265-273
57 Luo Q, Satcher Johnson A, Hall HI, Cahoon EK, Shiels M. Kaposi sarcoma rates among persons living with human immunodeficiency virus in the United States: 2008-2016. Clin Infect Dis 2020; •••: ciaa999
58 Grulich AE, Vajdic CM. The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol 2015; 42 (02) 247-257
59 Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med 2013; 137 (02) 289-294
60 Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers 2019; 5 (01) 9
61 Orenstein JM. Ultrastructure of Kaposi sarcoma. Ultrastruct Pathol 2008; 32 (05) 211-220
62 Northfelt DW, Dezube BJ, Thommes JA. et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16 (07) 2445-2451
63 Stewart S, Jablonowski H, Goebel FD. et al; International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1998; 16 (02) 683-691
64 Cianfrocca M, Lee S, Von Roenn J. et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010; 116 (16) 3969-3977
65 Chen I-Y, Ichinohe T. Response of host inflammasomes to viral infection. Trends Microbiol 2015; 23 (01) 55-63
66 Harland DL, Robinson WA, Franklin WA. Deletion of the p53 gene in a patient with aggressive burn scar carcinoma. J Trauma 1997; 42 (01) 104-107
67 Lee SH, Shin MS, Kim HS. et al. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000; 114 (01) 122-126
68 Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13 (07) 265-270
69 Treves N, Pack G. The development of cancer in burn scars. Surg Gynecol Obstet 1930; 51: 749-782
70 Novick M, Gard DA, Hardy SB, Spira M. Burn scar carcinoma: a review and analysis of 46 cases. J Trauma 1977; 17 (10) 809-817
71 Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 2017; 5 (01) 53
72 Allavena P, Sica A, Vecchi A, Locati M, Sozzani S, Mantovani A. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 2000; 177: 141-149
73 van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154 (06) 1685-1691
74 Brunet JF, Denizot F, Luciani MF. et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987; 328 (6127): 267-270
75 Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
76 Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480 (7378): 480-489
77 Seyfizadeh N, Seyfizadeh N, Gharibi T, Babaloo Z. Interleukin-13 as an important cytokine: a review on its roles in some human diseases. Acta Microbiol Immunol Hung 2015; 62 (04) 341-378
78 Kadin ME, Morgan J, Xu H. et al. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis. Hum Pathol 2018; 78: 54-62
79 Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130 (04) 829-842 , quiz 843–844
80 Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014; 7: 123-130
81 Lechner MG, Megiel C, Church CH. et al. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res 2012; 18 (17) 4549-4559
82 Monini P, Colombini S, Stürzl M. et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999; 93 (12) 4044-4058
83 Schulz TF, Cesarman E. Kaposi sarcoma-associated herpesvirus: mechanisms of oncogenesis. Curr Opin Virol 2015; 14: 116-128
84 Fedeles BI, Freudenthal BD, Yau E. et al. Intrinsic mutagenic properties of 5-chlorocytosine: a mechanistic connection between chronic inflammation and cancer. Proc Natl Acad Sci U S A 2015; 112 (33) E4571-E4580
85 de Bree E, van Coevorden F, Peterse JL, Russell NS, Rutgers EJ. Bilateral angiosarcoma of the breast after conservative treatment of bilateral invasive carcinoma: genetic predisposition?. Eur J Surg Oncol 2002; 28 (04) 392-395